Glaxosmithkline LLC
pharmaceutical company
Based in DC
🤖
AI Overview
With $1.4M in lobbying spend across 27 quarterly filings, Glaxosmithkline LLC is a significant lobbying presence.
$1.4M
Total Lobbying Spend
27
Quarterly Filings
1
Lobbying Firms Used
7
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $150K |
| 2020 | $200K |
| 2021 | $200K |
| 2022 | $150K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $10K |
Lobbying Firms
THORN RUN PARTNERS
What They Lobby For
- General health care coverage and reimbursement; implementation issues regarding the Patient Protection and Affordable Care Act; legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; and the Food and Drug Administration legislative and regulatory issues; H.R.4297, The Protecting Seniors Through Immunization Act of 2017.
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; H.R.4297, The Protecting Seniors Through Immunization Act of 2017.
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues;
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 19, Lower Costs, More Cures Act of 2019.
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; H.R. 19, Lower Costs, More Cures Act of 2019.
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; The Cares Act (P.L. 116-136).
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; H.R. 133, Consolidating Appropriations Act, 2021.
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031. H.R. 1978/S. 912, S.912 - Protecting Seniors Through Immunization Act of 2021.
- General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031. H.R. 1978/S. 912, S.912 - Protecting Seniors Through Immunization Act of 2021.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.